Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Denial Of Mucinex Petition Stops Reckitt's Bid To Delay Generics

This article was originally published in The Tan Sheet

Executive Summary

FDA stymies Reckitt Benckiser's attempt to delay private label competition for Mucinex OTC cough products by rejecting the firm's request to redefine bioequivalence standards for guaifenesin generics

You may also be interested in...



Perrigo Sets Generic Mucinex Launch After Patent Claim Decision

The private labeler clears a Reckitt Benckiser legal hurdle and will launch generic Mucinex (guaifenesin) by April. Watson has filed ANDAs for three Mucinex products and could be a good strategic partner for Perrigo, an analyst suggests.

Perrigo Sets Generic Mucinex Launch After Patent Claim Decision

The private labeler clears a Reckitt Benckiser legal hurdle and will launch generic Mucinex (guaifenesin) by April. Watson has filed ANDAs for three Mucinex products and could be a good strategic partner for Perrigo, an analyst suggests.

Perrigo Seeks To Slow Rivals’ Private-Label Prevacid Launches

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS103701

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel